Alnylam Pharmaceuticals Inc. (ALNY)

72.68
1.56 2.10
NASDAQ : Health Technology
Prev Close 74.24
Open 74.24
Day Low/High 72.02 / 74.95
52 Wk Low/High 60.27 / 124.22
Volume 966.17K
Avg Volume 924.50K
Exchange NASDAQ
Shares Outstanding 110.98M
Market Cap 8.08B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Alnylam Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of its previously announced underwritten registered public offering of 6,440,000 shares of its common stock,...

Alnylam Initiates Rolling Submission Of New Drug Application (NDA) To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Initiates Rolling Submission Of New Drug Application (NDA) To U.S. Food And Drug Administration (FDA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application (NDA) to the U.

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 5,600,000 shares of its common stock at a public offering...

European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment Of Patisiran For Patients With Hereditary ATTR (hATTR) Amyloidosis

European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment Of Patisiran For Patients With Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an...

Alnylam Pharmaceuticals Announces Proposed Public Offering Of $675,000,000 Of Common Stock

Alnylam Pharmaceuticals Announces Proposed Public Offering Of $675,000,000 Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of shares of its common stock to raise aggregate proceeds of...

Alnylam Announces Successful Outcome Following FDA Type A Meeting To Discuss Fitusiran Program In Hemophilia

Alnylam Announces Successful Outcome Following FDA Type A Meeting To Discuss Fitusiran Program In Hemophilia

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a successful Type A meeting with the U.

Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2017, and highlighted recent progress in advancing its...

Alnylam Initiates ENVISION Phase 3 Clinical Study With Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Initiates ENVISION Phase 3 Clinical Study With Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the initiation of the ENVISION Phase 3 clinical study with givosiran, a subcutaneously administered, investigational...

The Medicines Company And Alnylam Pharmaceuticals Announce Initiation Of Phase III Clinical Trials Of Inclisiran

The Medicines Company And Alnylam Pharmaceuticals Announce Initiation Of Phase III Clinical Trials Of Inclisiran

The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc.

Alnylam Reports Positive Preliminary Results From Ongoing Phase 1/2 Study Of Lumasiran (ALN-GO1) In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Reports Positive Preliminary Results From Ongoing Phase 1/2 Study Of Lumasiran (ALN-GO1) In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive preliminary data from its ongoing Phase 1/2 study with lumasiran (formerly known as ALN-GO1), an...

Notable Thursday Option Activity: ALNY, NTLA, IMMR

Notable Thursday Option Activity: ALNY, NTLA, IMMR

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alnylam Pharmaceuticals Inc , where a total volume of 8,996 contracts has been traded thus far today, a contract volume which is representative of approximately 899,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 93.8% of ALNY's average daily trading volume over the past month, of 959,440 shares.

Alnylam And Sanofi Present Positive Complete Results From APOLLO Phase 3 Study Of Investigational Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam And Sanofi Present Positive Complete Results From APOLLO Phase 3 Study Of Investigational Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today positive complete results from the APOLLO...

Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 26 th Annual Credit...

Alnylam To Webcast Conference Call Discussing Third Quarter 2017 Financial Results

Alnylam To Webcast Conference Call Discussing Third Quarter 2017 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2017 on Tuesday, November 7, 2017,...

Alnylam And Collaborators To Present APOLLO Phase 3 Study Results At 1st European ATTR Amyloidosis Meeting For Patients And Doctors

Alnylam And Collaborators To Present APOLLO Phase 3 Study Results At 1st European ATTR Amyloidosis Meeting For Patients And Doctors

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary ATTR (hATTR) amyloidosis patients with...

Alnylam And Vir Form Strategic Alliance To Advance RNAi Therapeutics For Infectious Diseases

Alnylam And Vir Form Strategic Alliance To Advance RNAi Therapeutics For Infectious Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an exclusive licensing agreement with Vir Biotechnology, a company dedicated to transforming the care of people...

Alnylam Initiates Phase 2 Clinical Study Of Cemdisiran (ALN-CC5) In Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Alnylam Initiates Phase 2 Clinical Study Of Cemdisiran (ALN-CC5) In Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 2 clinical study with cemdisiran (formerly known as ALN-CC5), a subcutaneously...

Alnylam Continues Leadership In RNAi Technologies And Delivery With New Pre-Clinical Data Presented On "Enhanced Stabilization Chemistry Plus" (ESC+) GalNAc-siRNA Conjugate Platform At 13th Annual Meeting Of The Oligonucleotide Therapeutics Society

Alnylam Continues Leadership In RNAi Technologies And Delivery With New Pre-Clinical Data Presented On "Enhanced Stabilization Chemistry Plus" (ESC+) GalNAc-siRNA Conjugate Platform At 13th Annual Meeting Of The Oligonucleotide Therapeutics Society

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the Company presented new pre-clinical data highlighting its next generation "Enhanced Stabilization Chemistry...

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam and Sanofi Genzyme announced positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy.

Alnylam And Sanofi Report Positive Topline Results From APOLLO Phase 3 Study Of Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam And Sanofi Report Positive Topline Results From APOLLO Phase 3 Study Of Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of...

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.

Alnylam Provides Pipeline Update On Fitusiran And Givosiran Investigational RNAi Therapeutic Programs

Alnylam Provides Pipeline Update On Fitusiran And Givosiran Investigational RNAi Therapeutic Programs

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company, announced today an update on the company's fitusiran and givosiran investigational RNAi therapeutic programs.

Alnylam To Webcast Presentation At 15th Annual Morgan Stanley Global Healthcare Conference

Alnylam To Webcast Presentation At 15th Annual Morgan Stanley Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 15 th Annual Morgan Stanley Global Healthcare...

Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2017, and highlighted recent progress in advancing its...

Alnylam To Webcast Conference Call Discussing Second Quarter 2017 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2017 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2017 on Wednesday, August 9, 2017,...

Alnylam To Host Fourth Annual "RNAi Roundtable" Webcast Series

Alnylam To Host Fourth Annual "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 4 th annual series of "RNAi Roundtable" webcasts this summer and early fall.

Tesla's Rally Has Died: Stock Falls to Sixth Worst Performer in Russell 1000

Tesla's Rally Has Died: Stock Falls to Sixth Worst Performer in Russell 1000

It was the seventh best performer in the index during the first half of the year.

Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new positive results from the ongoing...